Pathologic and clinical data for lymphoblastic lymphomas
. | Sex . | Age, y . | CD161 . | CD44 . | E2A . | ID2 . | TCF . | TCR . | 1A . | 1B . | KIR 2DL4 . | KIR 2D . | KIR 3D . | LDH . | Blast, % . | WBC . | HB . | PLT . | Med mass . | Stage . | ALL-like therapy* . | Survival, mo . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Uncommitted | ||||||||||||||||||||||
| 1 | F | 52 | – | + | – | C+ | – | – | – | – | – | – | – | 1298 | 70 | 22.1 | 10.4 | 32 | – | IV | No | 30 |
| 2 | F | 53 | – | – | + | – | – | – | – | – | – | – | – | NA | 0 | 7.2 | 15 | 194 | + | II | No | 120† |
| 3 | F | 29 | + | – | + | C+ | – | – | – | – | – | – | – | 419 | 30 | 10.7 | 12.1 | 434 | – | IV | No | 14 |
| T lineage | ||||||||||||||||||||||
| 4 | F | 7 | – | + | ND | – | – | + | – | – | – | – | – | 494 | 0 | 7.1 | 12.4 | 255 | + | III | Yes | 12 |
| 5 | M | 23 | + | – | + | C+ | – | + | – | – | – | – | – | 586 | 0 | 1.6 | 10.9 | 103 | – | IV | No | 21 |
| 6 | F | 69 | – | – | – | C+ | – | + | – | – | – | – | – | 373 | 0 | 7.6 | 3.5 | 52 | – | III | No | 1 |
| 7 | M | 33 | – | – | + | C+ | + | + | – | – | – | – | – | 2530 | 60 | 19.9 | 8.6 | 276 | – | IV | No | 18 |
| 8 | M | 43 | – | – | – | – | ND | + | – | – | – | – | – | 1970 | 57 | 4.7 | 3.5 | 44 | + | IV | No | 7 |
| 9 | M | 18 | – | – | + | C+ | + | + | – | – | – | – | – | 2340 | 0 | 5.6 | 11 | 190 | + | III | No | 1 |
| 10 | M | 29 | – | – | – | – | + | + | – | – | – | – | + | 577 | 0 | 8.7 | 13.9 | 280 | + | III | No | 14 |
| 11 | M | 28 | + | + | + | – | + | + | – | – | – | – | + | 289 | 6 | 7.4 | 16.1 | 166 | + | IV | No | 33 |
| 12 | M | 9 | + | + | – | C+ | + | + | – | – | – | – | + | 540 | NA | 2.8 | 8.2 | 125 | – | IV | Yes | 45 |
| 13 | M | 39 | – | + | ND | ND | ND | + | – | – | – | + | + | 908 | 0 | 5.6 | 14.1 | 313 | – | IV | No | 7 |
| 14 | M | 15 | + | – | + | C+ | – | + | – | – | – | – | + | 210 | 0 | 7.6 | 14.3 | 334 | – | III | Yes | 102† |
| NK lineage | ||||||||||||||||||||||
| 15 | M | 3 | – | – | + | – | + | – | + | + | – | – | + | 1900 | 0 | 7.5 | 3.6 | 10 | + | III | Yes | 34† |
| 16 | F | 19 | + | + | – | – | + | – | + | – | + | – | + | 247 | 12 | 9.1 | 13.3 | 129 | – | IV | No | 78† |
| 17 | F | 12 | + | – | – | – | + | – | + | – | – | – | + | NA | 0 | 7.2 | 13.5 | 271 | + | III | Yes | 105† |
| 18 | M | 27 | + | – | – | – | ND | – | + | – | – | + | – | 1407 | 0 | 6.1 | 13.3 | 232 | + | II | No | 108† |
| 19 | M | 12 | + | + | – | – | – | – | + | – | – | – | – | 372 | 0 | 5.2 | 13 | 238 | – | IV | Yes | 108† |
| 20 | M | 15 | + | + | – | – | + | – | + | – | – | – | – | 2353 | 23 | 15.3 | 12.2 | 92 | – | IV | Yes | 50† |
| 21 | F | 28 | + | + | + | – | + | – | + | + | – | – | – | 318 | 3 | 6.6 | 10.6 | 266 | – | IV | No | 45† |
. | Sex . | Age, y . | CD161 . | CD44 . | E2A . | ID2 . | TCF . | TCR . | 1A . | 1B . | KIR 2DL4 . | KIR 2D . | KIR 3D . | LDH . | Blast, % . | WBC . | HB . | PLT . | Med mass . | Stage . | ALL-like therapy* . | Survival, mo . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Uncommitted | ||||||||||||||||||||||
| 1 | F | 52 | – | + | – | C+ | – | – | – | – | – | – | – | 1298 | 70 | 22.1 | 10.4 | 32 | – | IV | No | 30 |
| 2 | F | 53 | – | – | + | – | – | – | – | – | – | – | – | NA | 0 | 7.2 | 15 | 194 | + | II | No | 120† |
| 3 | F | 29 | + | – | + | C+ | – | – | – | – | – | – | – | 419 | 30 | 10.7 | 12.1 | 434 | – | IV | No | 14 |
| T lineage | ||||||||||||||||||||||
| 4 | F | 7 | – | + | ND | – | – | + | – | – | – | – | – | 494 | 0 | 7.1 | 12.4 | 255 | + | III | Yes | 12 |
| 5 | M | 23 | + | – | + | C+ | – | + | – | – | – | – | – | 586 | 0 | 1.6 | 10.9 | 103 | – | IV | No | 21 |
| 6 | F | 69 | – | – | – | C+ | – | + | – | – | – | – | – | 373 | 0 | 7.6 | 3.5 | 52 | – | III | No | 1 |
| 7 | M | 33 | – | – | + | C+ | + | + | – | – | – | – | – | 2530 | 60 | 19.9 | 8.6 | 276 | – | IV | No | 18 |
| 8 | M | 43 | – | – | – | – | ND | + | – | – | – | – | – | 1970 | 57 | 4.7 | 3.5 | 44 | + | IV | No | 7 |
| 9 | M | 18 | – | – | + | C+ | + | + | – | – | – | – | – | 2340 | 0 | 5.6 | 11 | 190 | + | III | No | 1 |
| 10 | M | 29 | – | – | – | – | + | + | – | – | – | – | + | 577 | 0 | 8.7 | 13.9 | 280 | + | III | No | 14 |
| 11 | M | 28 | + | + | + | – | + | + | – | – | – | – | + | 289 | 6 | 7.4 | 16.1 | 166 | + | IV | No | 33 |
| 12 | M | 9 | + | + | – | C+ | + | + | – | – | – | – | + | 540 | NA | 2.8 | 8.2 | 125 | – | IV | Yes | 45 |
| 13 | M | 39 | – | + | ND | ND | ND | + | – | – | – | + | + | 908 | 0 | 5.6 | 14.1 | 313 | – | IV | No | 7 |
| 14 | M | 15 | + | – | + | C+ | – | + | – | – | – | – | + | 210 | 0 | 7.6 | 14.3 | 334 | – | III | Yes | 102† |
| NK lineage | ||||||||||||||||||||||
| 15 | M | 3 | – | – | + | – | + | – | + | + | – | – | + | 1900 | 0 | 7.5 | 3.6 | 10 | + | III | Yes | 34† |
| 16 | F | 19 | + | + | – | – | + | – | + | – | + | – | + | 247 | 12 | 9.1 | 13.3 | 129 | – | IV | No | 78† |
| 17 | F | 12 | + | – | – | – | + | – | + | – | – | – | + | NA | 0 | 7.2 | 13.5 | 271 | + | III | Yes | 105† |
| 18 | M | 27 | + | – | – | – | ND | – | + | – | – | + | – | 1407 | 0 | 6.1 | 13.3 | 232 | + | II | No | 108† |
| 19 | M | 12 | + | + | – | – | – | – | + | – | – | – | – | 372 | 0 | 5.2 | 13 | 238 | – | IV | Yes | 108† |
| 20 | M | 15 | + | + | – | – | + | – | + | – | – | – | – | 2353 | 23 | 15.3 | 12.2 | 92 | – | IV | Yes | 50† |
| 21 | F | 28 | + | + | + | – | + | – | + | + | – | – | – | 318 | 3 | 6.6 | 10.6 | 266 | – | IV | No | 45† |
1A indicates CD94 1A; 1B, CD94 1B; LDH, lactate dehydrogenase, IU/L; Blast, percentage of blasts in peripheral blood; WBC, white blood cell count, 103/μL; HB, hemoglobin level, g/dL; PLT, platelet count, 103/μL; Med mass, mediastinal mass; ALL, acute lymphoblastic leukemia; C, cytoplasmic; NA, not available; ND, not determined
Patients were treated with either ALL-like or CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone)-based regimens
The case was censored